Propagation and Dissemination Strategies of Transmissible Spongiform Encephalopathy Agents in Mammalian Cells.
Heumüller SE, Hornberger AC, Hebestreit AS, Hossinger A, Vorberg IM.
Int J Mol Sci. 2022 Mar 8;23(6):2909. doi: 10.3390/ijms23062909.
Transmissible spongiform encephalopathy in the 21st century: neuroscience for the clinical neurologist.
Brown P.
Neurology. 2008 Feb 26;70(9):713-22. doi: 10.1212/01.wnl.0000302186.10596.f6.
microRNA-146a as a biomarker for transmissible spongiform encephalopathy.
Pogue A, Zhao Y, Lukiw W.
Folia Neuropathol. 2022;60(1):24-34. doi: 10.5114/fn.2022.113561.
Prions: structure, function, evolution, and disease.
Casey C, Sleator RD.
Arch Microbiol. 2024 Nov 22;207(1):1. doi: 10.1007/s00203-024-04200-3.
Resistance of transmissible spongiform encephalopathy agents to decontamination.
Taylor DM.
Contrib Microbiol. 2001;7:58-67. doi: 10.1159/000060376.
Transmissible spongiform encephalopathies.
Sejvar JJ, Schonberger LB, Belay ED.
J Am Vet Med Assoc. 2008 Dec 1;233(11):1705-12. doi: 10.2460/javma.233.11.1705.
[Transmissible spongiform encephalopathy].
Koukolík F.
Cas Lek Cesk. 1998 Apr 20;137(8):227-30.
Laboratory activities involving transmissible spongiform encephalopathy causing agents: risk assessment and biosafety recommendations in Belgium.
Leunda A, Van Vaerenbergh B, Baldo A, Roels S, Herman P.
Prion. 2013 Sep-Oct;7(5):420-33. doi: 10.4161/pri.26533. Epub 2013 Sep 20.
Prion protein and the transmissible spongiform encephalopathy diseases.
Chesebro B.
Neuron. 1999 Nov;24(3):503-6. doi: 10.1016/s0896-6273(00)81105-8.
Working with transmissible spongiform encephalopathy agents.
Brown P, Abee CR.
ILAR J. 2005;46(1):44-52. doi: 10.1093/ilar.46.1.44.
